JP2020520640A5 - - Google Patents

Info

Publication number

JP2020520640A5

JP2020520640A5 JP2019563454A JP2019563454A JP2020520640A5 JP 2020520640 A5 JP2020520640 A5 JP 2020520640A5 JP 2019563454 A JP2019563454 A JP 2019563454A JP 2019563454 A JP2019563454 A JP 2019563454A JP 2020520640 A5 JP2020520640 A5 JP 2020520640A5

Authority

JP

Japan

Prior art keywords

item

mrna

polynucleotide

polypeptide

seq

Prior art date

2018-05-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108091033319 polynucleotide Proteins 0.000 claims description 94
• 239000002157 polynucleotide Substances 0.000 claims description 94
• 102000040430 polynucleotide Human genes 0.000 claims description 94
• 108020004999 messenger RNA Proteins 0.000 claims description 80
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 74
• 229920001184 polypeptide Polymers 0.000 claims description 55
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 55
• 239000000203 mixture Substances 0.000 claims description 39
• 230000003834 intracellular effect Effects 0.000 claims description 38
• 150000002632 lipids Chemical class 0.000 claims description 34
• 239000002105 nanoparticle Substances 0.000 claims description 31
• 239000008194 pharmaceutical composition Substances 0.000 claims description 24
• 102100030698 Interleukin-12 subunit alpha Human genes 0.000 claims description 20
• 108091008606 PDGF receptors Proteins 0.000 claims description 20
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 20
• 238000000034 method Methods 0.000 claims description 20
• 108700026244 Open Reading Frames Proteins 0.000 claims description 19
• 101710194995 Interleukin-12 subunit alpha Proteins 0.000 claims description 16
• 239000003937 drug carrier Substances 0.000 claims description 15
• 239000012528 membrane Substances 0.000 claims description 15
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 13
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 13
• 102000013462 Interleukin-12 Human genes 0.000 claims description 12
• 108010065805 Interleukin-12 Proteins 0.000 claims description 12
• 239000002246 antineoplastic agent Substances 0.000 claims description 12
• 229940117681 interleukin-12 Drugs 0.000 claims description 12
• 206010028980 Neoplasm Diseases 0.000 claims description 10
• 108091051828 miR-122 stem-loop Proteins 0.000 claims description 9
• 102000018697 Membrane Proteins Human genes 0.000 claims description 8
• 108010052285 Membrane Proteins Proteins 0.000 claims description 8
• 238000007385 chemical modification Methods 0.000 claims description 8
• 230000004069 differentiation Effects 0.000 claims description 8
• 108020005345 3' Untranslated Regions Proteins 0.000 claims description 7
• 201000011510 cancer Diseases 0.000 claims description 7
• 239000002773 nucleotide Substances 0.000 claims description 7
• 125000003729 nucleotide group Chemical group 0.000 claims description 7
• UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 6
• PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 6
• 108091066112 miR-122-1 stem-loop Proteins 0.000 claims description 5
• 108091057488 miR-122-2 stem-loop Proteins 0.000 claims description 5
• 238000011282 treatment Methods 0.000 claims description 5
• LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims description 4
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
• 108091007780 MiR-122 Proteins 0.000 claims description 4
• 229930185560 Pseudouridine Natural products 0.000 claims description 4
• PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 4
• -1 amino lipid Chemical class 0.000 claims description 4
• WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 4
• 150000001875 compounds Chemical class 0.000 claims description 4
• 239000002679 microRNA Substances 0.000 claims description 4
• DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims description 4
• CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 claims description 3
• 108020003589 5' Untranslated Regions Proteins 0.000 claims description 3
• 108700011259 MicroRNAs Proteins 0.000 claims description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
• 230000006023 anti-tumor response Effects 0.000 claims description 3
• 230000002601 intratumoral effect Effects 0.000 claims description 3
• KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 claims description 2
• MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 claims description 2
• JCNGYIGHEUKAHK-DWJKKKFUSA-N 2-Thio-1-methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O JCNGYIGHEUKAHK-DWJKKKFUSA-N 0.000 claims description 2
• BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 claims description 2
• GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims description 2
• FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 claims description 2
• HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 claims description 2
• VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 claims description 2
• DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 claims description 2
• BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 claims description 2
• YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 claims description 2
• QCNWZROVPSVEJA-UHFFFAOYSA-N Heptadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCC(O)=O QCNWZROVPSVEJA-UHFFFAOYSA-N 0.000 claims description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 2
• 229930182558 Sterol Natural products 0.000 claims description 2
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 2
• NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims description 2
• 239000000872 buffer Substances 0.000 claims description 2
• 229940040731 human interleukin-12 Drugs 0.000 claims description 2
• 238000002347 injection Methods 0.000 claims description 2
• 239000007924 injection Substances 0.000 claims description 2
• 150000003904 phospholipids Chemical class 0.000 claims description 2
• 150000003432 sterols Chemical class 0.000 claims description 2
• 235000003702 sterols Nutrition 0.000 claims description 2
• 239000000126 substance Substances 0.000 claims description 2
• JGSQPOVKUOMQGQ-VPCXQMTMSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methoxyoxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(OC)O[C@H](CO)[C@@H](O)[C@H]1O JGSQPOVKUOMQGQ-VPCXQMTMSA-N 0.000 claims 1
• SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims 1
• SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
• 239000007788 liquid Substances 0.000 claims 1
• 108091070501 miRNA Proteins 0.000 claims 1
• 230000000149 penetrating effect Effects 0.000 claims 1
• 230000004614 tumor growth Effects 0.000 claims 1
• 125000003275 alpha amino acid group Chemical group 0.000 description 22
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 21
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 21
• 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 20
• 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 20
• 108010076504 Protein Sorting Signals Proteins 0.000 description 8
• 239000003814 drug Substances 0.000 description 7
• 150000001413 amino acids Chemical class 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 239000012634 fragment Substances 0.000 description 6
• 102000008096 B7-H1 Antigen Human genes 0.000 description 4
• 108010074708 B7-H1 Antigen Proteins 0.000 description 4
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
• 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 4
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
• 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 4
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 229940045513 CTLA4 antagonist Drugs 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 229960003852 atezolizumab Drugs 0.000 description 2
• 229950002916 avelumab Drugs 0.000 description 2
• 229950009791 durvalumab Drugs 0.000 description 2
• 229940029575 guanosine Drugs 0.000 description 2
• 229960005386 ipilimumab Drugs 0.000 description 2
• 229960003301 nivolumab Drugs 0.000 description 2
• 229960002621 pembrolizumab Drugs 0.000 description 2
• 229950007217 tremelimumab Drugs 0.000 description 2
• UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 1
• JTMZHHMIEMBYNV-VITAEQTISA-N 2-amino-9-[(2r,3r,4s,5r)-2-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@]1(N=[N+]=[N-])O[C@H](CO)[C@@H](O)[C@H]1O JTMZHHMIEMBYNV-VITAEQTISA-N 0.000 description 1
• BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 description 1
• JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 description 1
• VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 description 1
• ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 1
• HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
• 241000180579 Arca Species 0.000 description 1
• 101150077194 CAP1 gene Proteins 0.000 description 1
• 101150014715 CAP2 gene Proteins 0.000 description 1
• 101710180456 CD-NTase-associated protein 4 Proteins 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 1
• 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1